Skip to medicine information
Protein Simülasyonları ve 3D Modelleme Medicine information · English

Baricitinib

What baricitinib treats

Baricitinib, marketed as Olumiant, is an oral Janus kinase inhibitor. The current U.S. label includes selected adults with rheumatoid arthritis, hospitalised adults with COVID-19 who meet specified respiratory-support criteria, and severe alopecia areata in adults and patients aged 12 years or older. These are distinct clinical uses. A hospital COVID-19 regimen is not a model for unsupervised treatment of an infection at home.

A different interaction pathway from some other JAK inhibitors

Baricitinib should not be assumed to share every interaction of upadacitinib or tofacitinib. Renal transport through OAT3 is particularly relevant. Probenecid, a strong OAT3 inhibitor, increases baricitinib exposure, and the prescribing information calls for a clinician-directed modification. By contrast, the label reports no clinically meaningful pharmacokinetic effect from studied fluconazole or rifampin coadministration. Those observations do not establish universal safety of a complete regimen.

Combining immune-active medicines

For chronic rheumatoid arthritis or alopecia treatment, the label does not recommend combination with other JAK inhibitors, biologic immunomodulators or potent immunosuppressants such as azathioprine or ciclosporin. This does not mean every conventional anti-inflammatory medicine is interchangeable or automatically prohibited. The treatment team should assess the whole regimen and indication, including infection history, vaccination plans and other prescribed immune-active medicines.

Monitoring and serious adverse effects

Renal function strongly influences baricitinib exposure and needs attention before and during prescribing. Blood counts, liver enzymes and lipid results may also require follow-up. Major JAK-inhibitor warnings concern serious infections, malignancies, cardiovascular events, thrombosis and mortality. Report a persistent fever or signs of serious infection promptly. Chest pain, sudden breathlessness, one-sided leg swelling, stroke-like symptoms or a serious allergic reaction warrant urgent assessment. New severe abdominal pain should also be evaluated.

Questions for the next medicine review

Ask which condition is being treated, which follow-up tests are due and what to do if an infection develops. Report nonprescription products as well as prescription medicines. Common adverse reactions differ between the arthritis, alopecia and COVID-19 datasets; examples include respiratory infections, nausea, herpes infections, headache and acne. Pregnancy planning and breastfeeding require an individual discussion. Human pregnancy evidence remains insufficient, and the U.S. label advises against breastfeeding during treatment and for a short interval after the last dose. Do not independently alter treatment based on this page.

Sources and scope

This English summary describes the referenced U.S. product information; local authorisations, age limits and formulations may differ. It is not a dosing guide or an independent clinical review. A missing interaction entry does not establish safety.